These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18464944)

  • 1. Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome.
    Cheng M; Hashmi S; Mao X; Zeng QT
    Can J Cardiol; 2008 May; 24(5):385-90. PubMed ID: 18464944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
    Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
    Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EFFECT OF RELATIVE GENE EXPRESSION ON PLAQUE VULNERABILITY IN PATIENTS WITH STABLE ANGINA AND PATIENTS WITH ACUTE CORONARY SYNDROME.
    Chen N; Zhang JY; Yang SZ; Li YD
    J Biol Regul Homeost Agents; 2015; 29(2):437-41. PubMed ID: 26122234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood levels of matrix and inflammatory mediators are elevated in Tunisian patients with acute coronary syndromes.
    Zayani Y; Allal-Elasmi M; Jacob MP; Zidi W; Zaroui A; Feki M; Mourali S; Mechmech R; Kaabachi N
    Clin Lab; 2013; 59(1-2):169-75. PubMed ID: 23505923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcription activity of MMP-2 and MMP-9 metalloproteinase genes and their tissue inhibitor (TIMP-2) in acute coronary syndrome patients.
    Dabek J; Glogowska-Ligus J; Szadorska B
    J Postgrad Med; 2013; 59(2):115-20. PubMed ID: 23793312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of atherosclerotic plaque stability and inflammation in the pathogenesis of acute coronary syndrome].
    Ding SF; Zhang Y; Zhang M; Chen WQ; Chen YG; Li JF; Ji QS; Li GS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Jun; 34(6):512-4. PubMed ID: 16842667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
    Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
    Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome.
    Derosa G; D'Angelo A; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; Cicero AF
    Heart Vessels; 2007 Nov; 22(6):361-70. PubMed ID: 18043992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
    Inokubo Y; Hanada H; Ishizaka H; Fukushi T; Kamada T; Okumura K
    Am Heart J; 2001 Feb; 141(2):211-7. PubMed ID: 11174334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The measurement of circulating matrix metalloproteinase-8 and its tissue inhibitor and their association with inflammatory mediators in patients with acute coronary syndrome.
    Allal-Elasmi M; Zayani Y; Zidi W; Zaroui A; Feki M; Mourali S; Mechmeche R; Kaabachi N
    Clin Lab; 2014; 60(6):951-6. PubMed ID: 25016699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease.
    Fitzsimmons PJ; Forough R; Lawrence ME; Gantt DS; Rajab MH; Kim H; Weylie B; Spiekerman AM; Dehmer GJ
    Atherosclerosis; 2007 Sep; 194(1):196-203. PubMed ID: 16942771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence.
    Pussinen PJ; Sarna S; Puolakkainen M; Öhlin H; Sorsa T; Pesonen E
    Int J Cardiol; 2013 Jul; 167(2):362-8. PubMed ID: 22257687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum MMP-9 Diagnostics, Prognostics, and Activation in Acute Coronary Syndrome and Its Recurrence.
    Lahdentausta L; Leskelä J; Winkelmann A; Tervahartiala T; Sorsa T; Pesonen E; Pussinen PJ
    J Cardiovasc Transl Res; 2018 Jun; 11(3):210-220. PubMed ID: 29349668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months.
    Derosa G; Cicero AF; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; D'Angelo A
    Endothelium; 2007; 14(4-5):175-83. PubMed ID: 17922333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-gamma increases the ratio of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in peripheral monocytes from patients with coronary artery disease.
    Springall R; Amezcua-Guerra LM; Gonzalez-Pacheco H; Furuzawa-Carballeda J; Gomez-Garcia L; Marquez-Velasco R; Mejía-Domínguez AM; Cossío-Aranda J; Martínez-Sánchez C; Bojalil R
    PLoS One; 2013; 8(8):e72291. PubMed ID: 23951304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients.
    Badra G; Lotfy M; El-Refaie A; Obada M; Abdelmonem E; Kandeel S; Fathy A
    Acta Microbiol Immunol Hung; 2010 Mar; 57(1):29-42. PubMed ID: 20350877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.